In the last few years, anti-PD1/PD-L1 drugs have become a new paradigm in oncology, and based on current research, anti-PD1 and anti-PDL1 antibodies combined with a MET inhibitor may finally represent an effective treatment of EGFR-mutant NSCLC. Here, MET is linked to non-small cell lung carcinoma.